All News
ICYMI
Interesting study by Dr LWGarcia et al:
👉IFN-a serum levels predicted failure to respond to tx 2 years after a flare in pts w/ LN
👉Pts w/⬆️BL IFN-a levels had greater risk of having 2 or more subsequent flares
#ACR23 ABST2297 @RheumNow @ZahiTouma https://t.co/WJZnNUPUbT
sheila ( View Tweet)
Q for Rheumatologists:
How often do you counsel appropriate SLE patients about cervical ca screening and/or vaccination?
Re: PAPILUP Study A#1479 #ACR23 - shows PAP findings of HR-HPV+abnml cytology comparable to HIV+ pts
@RheumNow
Eric Dein ( View Tweet)
Agimeteran a TLR7/8i 30 mg in #cutaneous #lupus which differentiated from placebo. Small single site #RCT. Far more pts improved #CLASI by 50% vs PBO #ACR23 #ACRbest @RheumNow @ACRheum L15 In larger RCT now! https://t.co/zssjgpydVY
Janet Pope ( View Tweet)
Burden of flare & organ damage of SLE pts from the Asia Pacific cohort:
Prevalence of organ damage at BL - 39%
Incidence of damage accrual: ~58 per 1000PY
Pts w/ >=2 flares accrued damage
Flares independently⬆️risk of damage accrual
#ACR23 ABST2261 @RheumNow @rheumarhyme https://t.co/nW34sI9FdP
sheila ( View Tweet)
#ACRbest Abstracts – Day 3
Today was a big day for the Plenaries, Curbside Consults, ACR Business meeting (and induction of our new ACR President Dr. Deborah Desir) and Late-Breaking Posters. Our hot-button reporters have compiled these #ACRbest abstracts for you! (November 14, 2023 at #ACR23)
Read ArticleUrinary biomarkers precede loss of kidney function for lupus nephritis
In Abstract 0850, Dr. Andrea Fava from Johns Hopkins presents research on the value of urinary biomarkers as measure of intrarenal inflammation.
Read Article
#ACR23 Abstr#2332 We need to compliment the Complement #SLE. Post-hoc analysis of SOC + PBO from Dapirolizumab Phase 2 RCT showed reduced response in patients who flared with low complement levels vs normal or persistent activity. To consider as a stratifier @RheumNow https://t.co/BcN6ExLD0s
Md Yuzaiful Md Yusof ( View Tweet)
Treatment of lupus nephritis #ACR23
Dall’Era M, Furie R, Mosca M
@RheumNow https://t.co/Md2DsOrY5F
Dr. Antoni Chan ( View Tweet)
Part 2: Clinical Year in Review #ACR23 https://t.co/Yb8Xh2UKFY
Mithu Maheswaranathan, MD ( View Tweet)
Lupus Nephritis and the Target with PR3+ in proliferative classes with more aggresive phenotype..
#Lupus biopsy.. #ACR23 https://t.co/fGJX57hWx4
dX.Martínez ( View Tweet)
Latest in Lupus Treatment at #ACR23
• Dr. Dall’Era & Dr. Furie
• Approach to Lupus Nephritis 🫘
• Treating Non-Renal SLE / Skin
#Lupus #RheumTwitter #Rheumatology https://t.co/sagVipdNJe
Mithu Maheswaranathan, MD ( View Tweet)
#Lupus #ACR23🦋
🌍A wonderful session unraveling scientific breakthroughs of #CAR T cell therapy
🔥Promising step towards future in revolutionizing Lupus T/t💡📑
💡Keeps efficacy of other vaccines intact!
Follow this thread showcasing other imp findings
#ACRambassador
1/2 https://t.co/aNFTmJiH0X
debaditya_roy ( View Tweet)
✅ Michelle Petri in the VERY FULL #ACR23 early session about #lupus:
BEFORE stepping-up with biologics, ask the key questions:
-Are you using proton-pump inhibitors (Drug-induced SCLE)
-Can I see your sunscreen?
-Can I see your hat?
-Are you smoking?
-Any HCQ blood levels? https://t.co/s73FqyjLOn
Laurent ARNAUD ( View Tweet)
Conundrum of #Clinically #Quiescent #Serologically #Active #SLE-half flare within 5 yrs; can have organ damage. Large cohort-China
20% met def’n- diff trajectories
37% flare
1/6 got damage in f/u
Some tapered Rx
How to identify safe to d/c Rx?
2555 #ACR23 @ACRheum @RheumNow https://t.co/f49BQspQsz
Janet Pope ( View Tweet)
#Lupus #nephritis - #inflammatory #fibrosis predicts #renal damage on #kidney #bx @ACRheum @RheumNow #ACR23 #2552 - similar in CRF from #Diabetes etc Biomarker is i-IFTA - same as other CRF diseases https://t.co/2LNn5Wn7rJ
Janet Pope ( View Tweet)
What % of pts in #RCTs in #SLE go in to #LLDAS - Pooling 5 RCTs - starting on #belimumab vs #placebo? More w #bDMARD @RheumNow @ACRheum #ACR23 abst#2551. True w DORIS - #lupus #rem but overall lower rates in each group https://t.co/VPZrYCVjof
Janet Pope ( View Tweet)
After attaining #remission or #LLDAS after a flare - HALF flare over f/u esp if tapering pred to <7.5 or 5 mg. #HCQ was protective. 65% got LLDAs and 45% rem in 1/2 yr - longer time to get #remission #2553 #ACR23 @RheumNow @ACRheum #ACRbest Asian cohort of #SLE largest@in world https://t.co/yBBqYJZVOe
Janet Pope ( View Tweet)
Wouldn’t it be great to assess immune changes in #SLE before #clinical #lupus #flare? Without over treatment too! YOU CAN
Lupus flare risk index calculated prior to disease activity change or stable pt. Results combined for score 11 mediators
#ACR23 @RheumNow @ACRheum abst#2554 https://t.co/gUimJLrJ33
Janet Pope ( View Tweet)
The Lupus APOL1 Story
Dr. Kathryn Dao talks with Dr. Ashira Blazer, Rheumatology Research Foundation Dubois Memorial Lecturer on APOL1 High Risk Genotype in SLE: A Genes in Context Story, at the 2023 ACR Convergence meeting in San Diego, CA. #ACR23
https://t.co/VXxJxk0kbS https://t.co/1n1COXcYA4
Dr. John Cush RheumNow ( View Tweet)